Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine

Asmar, Roland; Gosse, Philippe; Quéré, Stéphane; Achouba, Assya

doi:10.1097/mbp.0b013e328344c6db

Cited by 31 publications

(23 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among the patients using ABPM in this study, those with the 8‐week OA FDC showed greater SBP‐lowering effects than those receiving DA. Furthermore, the ABPM SBP reduction in our patients receiving the OA (20 mg/5 mg) FDC was greater than for the patients in another study receiving valsartan/amlodipine FDC (160 mg/5 mg) for 8 weeks where their BPs were uncontrolled by amlodipine (5 mg) [16].…”

Section: Discussioncontrasting

confidence: 62%

Efficacy and tolerability between an olmesartan/amlodipine fixed‐dose combination and an amlodipine double dose in mild to moderate hypertension

Lin

Tsai

Pan

et al. 2012

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

Fixed-dose combinations (FDCs) are one of the options for improving blood pressure (BP) goal attainment. We enrolled 141 patients and evaluated the efficacy and safety between a fixed dose of olmesartan/amlodipine (OA) and a double dose of amlodipine (DA) for treating mild to moderate hypertension after amlodipine monotherapy failure. After at least 2 weeks of monotherapy failure, the patients were randomized to receive either OA or DA for 8 weeks. We compared the systolic blood pressure (SBP)-lowering efficacy of the OA and DA using both an office BP and an ambulatory blood pressure monitoring (ABPM) device. The intent-to-treat analysis found that the early (2nd week) and final visit (8th week) SBP reductions were significantly greater in those patients receiving OA (n = 70) than DA (n = 71) (17.57 ± 15.49 vs. 10.46 ± 13.36 and 24.89 ± 14.09 vs. 17.03 ± 13.27 mmHg, p = 0.002 and 0.001, respectively). Among those using ABPM, the patients with 8-week OA had a greater SBP-lowering effect in comparison with those on DA (14.08 ± 10.74 vs. 6.32 ± 10.21, p = 0.018). Both treatment strategies were well tolerated. This study showed that an OA FDC is more effective than DA in reducing SBP for mild to moderate hypertension after the failure of amlodipine monotherapy.

show abstract

Section: Discussioncontrasting

confidence: 62%

Efficacy and tolerability between an olmesartan/amlodipine fixed‐dose combination and an amlodipine double dose in mild to moderate hypertension

Lin

Tsai

Pan

et al. 2012

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis has shown that in hypertensive patients, every 10 mmHg increase in night-time BP is associated with a 15% higher cardiovascular risk also after controlling for daytime BP [15]. In the setting of OSA, night-time BP surges, a nondipping BP profile and increased BP variability are characteristic [16][17][18], though data have not been consistent [19]. Accordingly, in the Heart Outcomes Prevention Evaluation study, evening dosing of ramipril was associated with a decreased cardiovascular risk, despite the only mild decreases in clinic BP, a fact that was attributed to better night-time BP control [20].…”

Section: Discussionmentioning

confidence: 95%

Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea

Κασιακόγιας

Tsioufis

Thomopoulos

et al. 2015

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…We thus conducted the statistical analysis to test for noninferiority against a one‐sided alternative hypothesis at the 2.5% significance level and a power of 80%. By assuming a standard deviation for the changes in nocturnal BP of 7.0 mm Hg and a clinically significant difference in the nocturnal brachial SBP reduction between the morning and bedtime administrations from the baseline of 0.43 mm Hg (based on a previous report), the sample size would be 23 patients. Adjusting by 10% for loss to follow‐up or dropout of patients, a final total of 26 patients were needed at randomization.…”

Section: Methodsmentioning

confidence: 99%

Comparison of morning vs bedtime administration of the combination of valsartan/amlodipine on nocturnal brachial and central blood pressure in patients with hypertension

Fujiwara

Hoshide

Yano

et al. 2017

J of Clinical Hypertension

View full text Add to dashboard Cite

The aim of this study was to compare the effect of morning and bedtime administration of valsartan/amlodipine combination therapy (80/5 mg) on nocturnal brachial and central blood pressure (BP) measured by ambulatory BP monitoring in patients with hypertension. This was a 16‐week prospective, multicenter, randomized, open‐label, crossover, noninferiority clinical trial. Patients underwent 24‐hour ambulatory BP monitoring at randomization, at switching, and at the end of the study. Twenty‐three patients (mean age, 68.0 years) were studied. The difference in nocturnal brachial systolic BP between the morning and bedtime administrations of combination valsartan/amlodipine was −3.2 mm Hg, and the two‐sided 95% confidence interval ranged from −6.8 to 0.4 mm Hg. The difference in nocturnal central systolic BP was −4.0 mm Hg (95% confidence interval, −7.6 to −0.4 mm Hg). The upper limit of the 95% confidence interval was below the margin of 3.0 mm Hg in both nocturnal brachial and central systolic BP, confirming the noninferiority of morning administration to the bedtime administration of valsartan/amlodipine combination therapy.

show abstract

Efficacy of morning and evening dosing of amlodipine/valsartan combination in hypertensive patients uncontrolled by 5 mg of amlodipine

Abstract: These results indicate that, in patients with BP uncontrolled by amlodipine (5 mg), morning and evening treatment with amlodipine/valsartan combination have similar effects on circadian BP, especially when 24-h mean values are considered.

Cited by 31 publications

References 20 publications

Efficacy and tolerability between an olmesartan/amlodipine fixed‐dose combination and an amlodipine double dose in mild to moderate hypertension

Efficacy and tolerability between an olmesartan/amlodipine fixed‐dose combination and an amlodipine double dose in mild to moderate hypertension

Evening versus morning dosing of antihypertensive drugs in hypertensive patients with sleep apnoea

Comparison of morning vs bedtime administration of the combination of valsartan/amlodipine on nocturnal brachial and central blood pressure in patients with hypertension

Contact Info

Product

Resources

About